Adaptimmune Therapeutics (ADAP) Announces Proposed 12.5M ADS Offering

Adaptimmune Therapeutics plc (NASDAQ: ADAP) today announced that it intends to offer and sell 12,500,000 American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price. All of the ADSs in the offering are to be sold by Adaptimmune, with net proceeds to be used to advance the development of Adaptimmune’s immunotherapies into and through clinical trials as well as for other general corporate purposes.

Cowen and SVB Leerink are acting as joint book-running managers for the offering and Roth Capital Partners is acting as lead manager for the offering.

You May Also Be Interested In

• Autodesk establishes $2B commercial paper program
• Cadrenal Therapeutics (CVKD) files for 2.94M share offering by sellign stockholders
• Samos Energy raises $230M in NYSE IPO for energy acquisitions